The first proposal approved the issuance of additional shares of the company's common stock, exceeding 20% of the outstanding shares, to Lind Global Asset Management XII LLC. This move is aimed at complying with NYSE American Rule 713, which governs the issuance of shares. The voting results showed strong support for this proposal, with 44,152,648 votes in favor, 14,095,382 against, and 1,114,276 abstentions. Additionally, there were 21,146,445 broker non-votes, indicating a robust engagement from shareholders.
The second proposal involved an amendment to the company's Second Amended and Restated Certificate of Incorporation to authorize a reverse stock split of the company's outstanding shares of common stock at a ratio between 1-for-5 and 1-for-20, as determined by the board of directors. This proposal received overwhelming approval, with 62,838,654 votes for, 16,451,299 against, and 1,218,798 abstentions. The reverse stock split is anticipated to enhance the company's stock price and improve its market perception.
These decisions are pivotal for VolitionRx as they navigate their growth strategy and seek to strengthen their financial position. The approval of the share issuance allows the company to raise capital, which is crucial for funding ongoing operations and potential expansions. Meanwhile, the reverse stock split is expected to consolidate shares, potentially attracting institutional investors and improving liquidity in the market.
Overall, the outcomes of the special meeting reflect a proactive approach by VolitionRx to manage its capital structure effectively and position itself for future growth opportunities. Investors will be keen to see how these changes will influence the company's stock performance in the coming months.
